Curis, Inc. (CRIS)
0.4534
-0.02
(-3.41%)
USD |
NASDAQ |
Nov 20, 09:50
Curis Cash from Investing (Quarterly) : 0.00 for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.00 |
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 2.50M |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | -0.428M |
| September 30, 2024 | 18.32M |
| June 30, 2024 | -7.361M |
| March 31, 2024 | 18.91M |
| December 31, 2023 | 14.52M |
| September 30, 2023 | 0.18M |
| June 30, 2023 | -3.154M |
| March 31, 2023 | 26.24M |
| December 31, 2022 | 3.463M |
| September 30, 2022 | 4.303M |
| June 30, 2022 | 28.34M |
| March 31, 2022 | -3.083M |
| December 31, 2021 | -3.523M |
| September 30, 2021 | -11.53M |
| June 30, 2021 | -28.77M |
| March 31, 2021 | -4.071M |
| December 31, 2020 | -53.47M |
| September 30, 2020 | -0.162M |
| Date | Value |
|---|---|
| June 30, 2020 | -0.258M |
| March 31, 2020 | 4.841M |
| December 31, 2019 | 1.549M |
| September 30, 2019 | 1.453M |
| June 30, 2019 | -8.058M |
| March 31, 2019 | 0.60M |
| December 31, 2018 | 4.654M |
| September 30, 2018 | 4.679M |
| June 30, 2018 | 13.81M |
| March 31, 2018 | -1.773M |
| December 31, 2017 | -2.571M |
| September 30, 2017 | 4.935M |
| June 30, 2017 | -6.012M |
| March 31, 2017 | 0.018M |
| December 31, 2016 | 14.06M |
| September 30, 2016 | 20.23M |
| June 30, 2016 | 5.127M |
| March 31, 2016 | -9.291M |
| December 31, 2015 | 15.66M |
| September 30, 2015 | 2.765M |
| June 30, 2015 | 15.73M |
| March 31, 2015 | -40.58M |
| December 31, 2014 | 5.254M |
| September 30, 2014 | 0.676M |
| June 30, 2014 | 6.902M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | -5.147M |
| Agenus, Inc. | -19.88M |
| Amgen, Inc. | -649.00M |
| Anika Therapeutics, Inc. | -1.756M |
| BioCryst Pharmaceuticals, Inc. | -78.88M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.749M |
| Cash from Financing (Quarterly) | 5.69M |
| Free Cash Flow | -30.77M |
| Free Cash Flow Per Share (Quarterly) | -1.376 |
| Free Cash Flow to Equity (Quarterly) | -5.445M |
| Free Cash Flow to Firm (Quarterly) | -5.749M |
| Free Cash Flow Yield | -1.65K% |